MalarVx
Biotechnology · Infectious Disease Therapeutics
$1.2Mtotal raised · 2 rounds on record
$125klatest round · Convertible Note · Aug 2026 · 3 mo ago
$5Mrevenue · 2025 · SEC Form D 0001559688-26-000003
10+team · employees, estimated range
Overview
THE COMPANY - MALARVX MalarVx Inc. is a biopharmaceutical company focused on developing an effective malaria vaccine.
Funding and backers
Total raised
$1.2M
2 rounds on record
Latest round
$125k
Convertible Note · Aug 2026 · 3 mo ago
Team
11-50
employees, estimated range
Revenue
$5M
2025 · SEC Form D 0001559688-26-000003
The money's age
Fresh money
3 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 8
Raised a round Convertible Note $125k · SEC Form D
Jan 2, 2015
Raised a round Venture round $1.1M · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Convertible Note | Aug 2026 | $125k | — | SEC Form D |
| Venture round | Jan 2015 | $1.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | MalarVx, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Jodi HerczegExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Genvax Technologies is an animal vaccine company developing next-generation mRNA + nanoparticle vaccines from Ames, Iowa. Our mission is to…
Gamgee is developing personalised mRNA vaccines as a cancer treatment for dogs, built from each dog’s tumour. See how it works with vets…
Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation adjuvanted subunit vaccines to the market…
SpyBiotech is a clinical stage biotechnology company with novel vaccine platform technologies to target infectious diseases, cancer and…
TareBio develops vaccines for cancer and infectious diseases by decoding immune responses to engineer targeted antigens.
Clinical Phase 2 Study - BE RESPONDER!. Cytuvax has completed the Phase 2 BE RESPONDER! clinical study to investigate the immunogenicity…
People
Jodi Herczeg
Executive Officer
James Davie
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Seattle
United States
HQ
10-50 est. staff